Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection
Floriane Gallais(Inserm), Samira Fafi‐Kremer(Centre National de la Recherche Scientifique), Aurélie Velay(Inserm), Timothée Bruel(Centre National de la Recherche Scientifique), Sophie Bayer, Nathalie Reix, Pierre Gantner(Inserm), Delphine Planas(Centre National de la Recherche Scientifique), Catherine Schmidt‐Mutter(Inserm), Baptiste Panaget(Inserm), Yves Hansmann(Hôpitaux Universitaires de Strasbourg), Arnaud Fontanet(Conservatoire National des Arts et Métiers), Olivier Schwartz(Centre National de la Recherche Scientifique), Morgane Solis(Inserm), Laurence Kling-Pillitteri, Nicolas Collongues(Inserm), Ludovic Glady, Maria Gonzalez, Anne Schneider, David Rey, Nicolás Meyer, Marialuisa Partisani, Jean‐Marc Lessinger, de Sèze(Université de Strasbourg), Marie-Josée Wendling(Institut de Virologie), Elodie Laugel(Inserm)
Cited by 239
Related Papers
Neuromyelitis Optica and Non–Organ-Specific Autoimmunity
|Archives of Neurology|2008|611
Syncytia formation by SARS‐CoV‐2‐infected cells
|The EMBO Journal|2020|497
Brain MRI Findings in Severe COVID-19: A Retrospective Observational Study
|Radiology|2020|471
Diagnosis and classification of optic neuritis
|The Lancet Neurology|2022|290
Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion
|Nature Communications|2024|237